Business Wire

Board Unveils New Foresight and Signals Products: Revolutionizing Business Planning with AI and Economic Intelligence

19.2.2025 15:00:00 CET | Business Wire | Press release

Share

Board, the leading Enterprise Planning Platform, is transforming the way businesses anticipate and adapt to economic shifts with today’s announcement of Board Foresight and Board Signals. These cutting-edge solutions, developed as a result of Board’s recent acquisition of Prevedere, empower enterprises with real-time economic indicators, predictive analytics, and the expertise of Board’s in-house economists—all backed by exclusive access to over 5 million global datasets.

This release marks a huge step forward in completing Board’s product vision. By harnessing the power of macroeconomic intelligence, the Board Enterprise Planning Platform now enables more comprehensive, collaborative, and continuous planning capabilities than ever before. Board Foresight and Signals give business leaders the ability to look beyond internal historical data, forecast with greater accuracy, scenario plan with more agility, and make strategic decisions with confidence in an increasingly volatile world.

Board Foresight: Continuous planning with external data, AI, and predictive analytics

Board Foresight takes business forecasting to the next level by unlocking the power of external data with expert-curated economic indicators, an advanced correlation engine, and predictive analytics. With real-time updates from millions of external sources, Board Foresight enables enterprises to anticipate market shifts, align business strategies and drive continuous planning.

Key benefits of Board Foresight:

  • Expert-Curated Indicators: Get a list of the external factors most likely to impact your industry.
  • Powerful Correlation Engine: Connect to your own internal time series data and Foresight will run millions of models to identify your most relevant performance drivers.
  • Results Explained by AI: Get a complete understanding of the external factors impacting your business, with clear explanation and interpretation delivered through generative AI.
  • Predictive Forecasting to Support Continuous Planning: Forecast with better accuracy and turn continuous planning into a competitive advantage.

Learn more at https://www.board.com/en/product/foresight.

Board Signals: Make smarter strategic decisions with expert-curated external data

Board Signals provides decision-makers with real-time, industry-specific economic indicators to help them navigate market volatility with confidence. Designed for strategic planners, executive officers, and board members, Board Signals delivers clear, actionable intelligence to drive smarter business decisions and is available today.

Key benefits of Board Signals:

  • Industry-Specific Economic Intelligence: Get expert-curated indicators tailored to your industry, monitored and updated regularly by Board’s in-house economists.
  • Smart Alerts on Market Volatility: Receive real-time alerts on headwinds and tailwinds impacting your business so you can respond in an agile manner to capitalize on opportunities and mitigate risks.
  • Indicator Reports and Industry Outlook Score: Visualize economic conditions with intuitive reports and scoring to support strategic decision-making.

Learn more at https://www.board.com/en/product/signals.

An Innovative Breakthrough in Enterprise Planning

David Marmer, SVP of Product at Board, emphasized the significance of these new solutions:

“The introduction of Board Foresight and Board Signals marks a new beginning for enterprise planning. For too long, businesses have relied solely on historical internal data, missing the critical external factors that drive success or failure. With the power of over 5 million datasets, AI-driven analytics, and expert economic intelligence, our customers can now plan continuously for the future with greater confidence and precision. These innovations reflect Board’s commitment to giving our customers the tools they need to stay ahead.”

Visionary Brands are Leading the Way

Leading enterprises are already leveraging Board Signals and Board Foresight to enhance their decision-making. Milwaukee Tool, Whataburger, and Kraft Heinz are among the early adopters benefiting from these solutions, using them to navigate economic volatility, optimize inventory, and drive strategic growth.

“This has been a game-changer for Whataburger,” says Pete Valadez, Senior Director of Financial Planning & Analysis at Whataburger. “By incorporating external data and predictive analytics into our forecasting process, we’ve been able to dramatically improve our accuracy and avoid missed expectations. The real-time alerts and collaborative nature of the solution have empowered our entire team to make data-driven decisions with confidence.”

General Availability

Board Signals and Board Foresight are available now globally.

About Board

The Board Enterprise Planning Platform powers financial and operational planning for more than 2,000 organizations worldwide. Industry leaders trust Board to turn complex data into better decisions with AI, analytics, and tailor-made solutions for enterprise-grade challenges. Global brands including H&M, BASF, Burberry, Toyota, Coca-Cola, KPMG, and HSBC use Board to enhance workflows and strengthen their competitive edge. Founded in 1994, and now with 25 offices worldwide, Board is recognized by leading analysts including Gartner, IDC, and BARC.

For more information, visit www.board.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250219004034/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release

-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release

A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper

Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release

Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user

Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release

Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin

Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye